看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。, u# }+ L& l: v+ H. b
/ a/ p t' i) [$ Z& D( S& m" V5 z. d- \* Z. ^5 A
Currently available feasibility data for possible combination strategies.
% E. L0 X& k; O b0 R/ o% P————————————————————————————————, y/ G* J B, z, f
Combination Feasibility according to preliminary data $ K. l6 A1 h! O) T( s. T: o
——————————————————————————————————
) Y* I* E! Q+ ^/ H- n0 F( C, M+ DBevacizumab + sorafenib Yes, reduced dose ( r9 A# e2 M! n
Bevacizumab + sunitinib† No
! W& G+ n9 O8 G( ?8 F- n5 hBevacizumab + temsirolimus Yes 2 a' D. `1 y$ @
Bevacizumab + everolimus Yes
7 R v) T5 i* l+ Y, eSorafenib + sunitinib ? 3 r2 R. r1 |0 l, h
Sorafenib + temsirolimus Yes, reduced dose
# m3 ]& g* b$ _Sorafenib + everolimus Yes, reduced dose
& A5 c, v: t" Q3 X- ~. `Sunitinib + temsirolimus† No , k8 c( i7 @1 c" t# W' B% r
Sunitinib + everolimus ?
* u: j; y/ ?0 ~. {Temsirolimus + everolimus ? # {8 \$ a# m3 U8 R: D1 g6 n
————————————————————
* d8 [0 e. k9 {†Led to US FDA warning.
. P" z8 r& } g9 s+ }. v, O?: As yet unattempted combination.
% G* D& o7 v( L" h: t$ |$ |' Z$ T |
显身卡
# ^4 s5 [7 {4 {6 ]! ~
